## **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

		wasnington, D.C. 20549	
		Form 8-K	
	of Tho	Current Report ursuant to Section 13 or 15(d) e Securities Exchange Act of 1934	
	Date of Report (D	ate of earliest event reported): Ju	ne 16, 2022
		DICINOVA, INC	
	DELAWARE (State or other jurisdiction of incorporation)	001-33185 (Commission File Number)	33-0927979 (I.R.S. Employer Identification No.)
	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA, CA (Address of principal executive offices)		92037 (Zip Code)
	Registrant's telep	hone number, including area code: (858)	373-1500
	(Former na	Not applicable. ame or former address, if changed since last report	i.)
	ck the appropriate box below if the Form 8-K filing is in the provisions (see General Instruction A.2. below):	ntended to simultaneously satisfy the filing	g obligation of the registrant under any of the
	Written communications pursuant to Rule 425 under	the Securities Act (17 CFR 230.425)	
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
	Pre-commencement communications pursuant to Rul	e 13e-4(c) under the Exchange Act (17 CF	R 240.13e-4(c))
Sec	urities registered pursuant to Section 12(b) of the Act:		
	Common Stock, \$0.001 par value	MNOV	The Nasdaq Stock Market LLC
	(Title of each class)	(Trading symbol(s))	(Name of each exchange on which registered)
	cate by check mark whether the registrant is an emergineter) or Rule 12b-2 of the Securities Exchange Act of 19		of the Securities Act of 1933 (§230.405 of this
			Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

## Item 5.02 Departure of Directors or Certain Officers; Election; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective June 16, 2022, Douglas Paulin resigned as Chief Financial Officer of MediciNova, Inc. (the "Company").

In addition, effective June 16, 2022, the Board appointed Jason J. Kruger, CPA (inactive), of the accounting services firm Signature Analytics ("Signature Analytics") to serve as Chief Financial Officer and Principal Financial Officer of the Company. Mr. Kruger replaces Mr. Paulin. Mr. Paulin had also served as the Company's Chief Financial Officer through a services agreement (the "Services Agreement") between the Company and Signature Analytics. Under the Services Agreement, as amended, the Company will continue to pay pre-approved hourly rates for the services provided under the Services Agreement. The current term of the Services Agreement, as amended, will expire on August 1, 2022 with automatic annual renewals, subject to earlier termination according to its terms.

Mr. Kruger, age 45, is the president and founder of Signature Analytics since September 2008. From January 2003 until September 2008, Mr. Kruger served as Senior Manager for Deloitte & Touche LLP. From July 1999 to January 2003 Mr. Kruger served as a Senior Accountant for Moss Adams LLP. Mr. Kruger received a Bachelor of Science in Business Administration Accounting and Finance from the University of Arizona.

There are no family relationships between Mr. Kruger and any of the Company's other directors or executive officers, and Mr. Kruger does not have any direct or indirect material interests in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

## **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## MEDICINOVA, INC.

By: /s/ Yuichi Iwaki

Yuichi Iwaki

President and Chief Executive Officer

Date: June 21, 2022